POTENTIATION OF LITHIUM WITH CARBAMAZEPINE IN ACUTE MANIA by Gangadhar, B.N. et al.
Indian Journal of Psychiatry, January 1987, 29(1), pp. 73-75 
POTENTIATION OF LITHIUM WITH CARBAMAZEPINE IN 
ACUTE MANIA 
B. N. GANGADHAR
1 
NIMESH G. DESAI
1 
S. M. CHANNABASAVANNA
1 
SUMMARY 
In a 6 month prospective randomized open trial addition of 400 mgs. of carbamazepine per day to 
lithium carbonate was assessed. Although statistically non-significant, the trends suggest that use of carbamazepine 
hastens recovery and leads to less frequent use of emergency sedation without any increase in side effects. 
While lithium carbonate has been 
found to be the most effective drug in treat-
ment of acute mania, other drugs like sod-
ium valporate, verapramil and carbamazep-
ine are also in use. Of these drugs carbama-
zepine has been of intensive research focus 
as a therapeutic and prophylactic agent for 
affective disorders. Combining carbama-
zepine and lithium carbonate is proved to 
be effective in refractory or treatment resis-
tant mania (Desai et al. 1983, Keishing, 
1983, Elphick 1985) suggesting a favour-
able therapeutic interaction between these 
two drugs. The possibility of using such an 
interaction in routine treatment of mania 
has not so far been considered. Hence, we 
attempted to compare lithium alone and li-
thium with fixed dose of carbamazepine in 
acute mania with respect to the clinical effi-
cacy, side effects and the need for emer-
gency sedation. 
Material and Methods 
Over a six months period patients with a 
diagnosis of mania were considered for this 
study with the following criteria. 
Inclusion - (1) Diagnosis of Manic Episode 
as per DSM-III (APA 1980). (2) Age bet-
ween 18 and 45 years. 
Exclusion - (1) Past history of non-re-
sponse to lithium (2) Current episode alrea-
dy on treatment (3) Patients on lithium or 
any other psychotropic medication in last 6 
months (4) Contraindication for lithium or 
carbamazepine therapy, including renal 
function tests. 
All patients were hospitalised after ob-
taining consent from a relative for the pro-
posed trial. These patients were randomly 
allocated to receive carbamazepine 200 
mgs. twice daily with lithium carbonate (Li 
+ CBZ group) or lithium carbonate (Li 
alone group). For all patients lithium car-
bonate was stepped up from an initial dose 
of 900 mgs. per day to higher doses to reach 
therapeutic range of 0.8 to 1.2 mEq/L in 
serum within first 10 days. At the end of the 
4 week trial period carbamazepine was dis-
continued. Lithium carbonate was conti-
nued for patients of both the groups for six 
months unless there was an indication for 
prophylaxis in which case the duration was 
longer than 6 months. 
The clinical state was rated on the Bech 
Rafaelsen Mania Scale (BRMS) (Bech et al. 
1979) pre-treatment and at weekly inter-
vals by two raters and their rating scores 
were averaged for each occasion. An overall 
clinical global rating of mania was done on 
a 0-15 scale. A check list consisting of equal 
number of common side effects described 
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for lithium and carbamazepine was used for 
weekly ratings. Intravenous injections of 10 
mgs. ol haloperidol were permitted to be 
used for emergency sedation in the ward as 
per the decision of the ward resident. 
Results 
Ten patients, five in each group (seven 
female, three males, age range 19-43 years) 
were included for the trial after screening 
24 patients. The patients in the two groups 
did not differ with respect to relevant clini-
cal variable including the pre-treatment 
(Wk 0) BRMS scores. 
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Fig. 1 . Mean ± SEM scores on BRMS in the two 
groups of patients. 
As is evident in the figure there was a 
trend towards a larger fall in BRMS scores 
in the Li + CBZ group. A 50% reduction in 
the original score occurred within one 
week in the Li + CBZ group while the 
same required two weeks in the Li alone 
group. All patients of the combination 
group reached a score of zero at the end of 4 
weeks whereas in the Li alone group only 
two patients reached a score of zero at 4 
weeks and one patient did not show any re-
sponse at all. This patient responded in the 
next two weeks with addition of carbama-
zepine. Global rating of mania also show si-
milar trends. 
The mean values of BRMS scores at pre-
trial or Wk 0 rating did not differ significantly 
between the two groups (t = 1.19 NS) sug-
gesting that the two groups of patients were 
comparable in the severity of mania. Inter 
group comparison of the mean BRMS scores 
on test did not reveal significant differences 
on any of the later occasions. 
Intra group comparison of the mean 
BRMS scores at each of the later occasions 
(Wk 1 to Wk 4) with the pre-trial (Wk 0) 
mean BRMS scores showed a significant re-
duction of symptoms in both the groups on 
all occasions. This period effect observed in 
both the group proves that significant im-
provement occurred during each of the 
four weeks with lithium-carbamazepine 
combination as well as lithium alone. The 
higher values seen for the combination group 
suggests that the improvement occurred at a 
faster rate in the combination group. 
Table shows: two patients in the Li + 
CBZ combination group reported one side 
effect each during the trial whereas three 
patients in the control group reported two 
symptoms each. This indicates that addi-
tion of carbamazepine to lithium does not 
lead to increased side effects. 
The number of injections used for emer-
gency sedation with haloperidol also differed 
in the two groups. The patients in the combi-
nation group required two injections in the 
first week and none in the next three weeks. 
The group of patients who received lithium 
alone needed twelve injections in the first 
week, six in the second week and one each in 
the third and fourth weeks. 
Discussion 
The trends observed in this study sup-
port earlier views (Nolen 1983, Lipinsky 
& Pope 1982) of a possible synergistic ac-
tion of lithium carbonate and carbamazep-
ine in mania. We have explored the possi-
bility of achieving an advantage by combin-
ing a fixed dose of carbamazepine (400 mgs. 
per day) to lithium carbonate. The higher 
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Table 
Li + CBZ Group (N = 5) Li alone Group (N = 5) 
Wk 0 Wk 1 Wk 2 Wk 3 Wk 4 Wk 0 Wk 1 Wk 2 Wk 3 Wk 4 
BRMS Score 
(Mean + S. D) 
Y Value with 
Wk 0 (Compared to 
baseline Mean) 
22.6 
± 4.3 
10.6 
± 3.8 
14.34 
<.001 
5.2 
± 2.6 
9.63 
<.001 
1.6 
± 0.8 
9.68 
<.001 
0 
4.00 
<.01 
26 
± 2.0 
15.8 
± 2.5 
2.70 
<.05 
12.4 
± 3.4 
2.99 
<.05 
8.8 
± 3.9 
3.25 
<.05 
8.6 
± 4.5 
3.06 
<.05 
ridol in the lithium alone group is likely to 
have lowered the BRMS scores, thus nar-
rowing the differences between the groups. 
The non-responder in lithium alone group 
showing good response after addition of 
carbamazepine further substantiates our 
earlier finding ot the efficacy of carbama-
zepine lithium combination for lithium re-
sistant mania (Desai et al. 1986). 
Besides the small sample size and poor 
control over other emergency medication, 
the open design of this study prevent us 
from drawing any definite conclusions of 
the suggestive trends of faster improve-
ment with the combination. The raters' bias 
in such a design may have worked either 
way and hence we have undertaken a 
double-blind placebo controlled study on 
similar lines. 
The finding of potentiating action of 
carbamazepine on lithium in acute mania, if 
confirmed in later studies, is likely to be 
useful in routine clinical practice by reduc-
ing the period of incapicitation or hospitali-
zation. This is all the more so since there 
seems to be no increase in the side effects. 
The issues of the period for which such a 
combination should be used and whether 
carbamazepine should be used in a fixed 
dose regimen or more flexibly are certainly 
open to debate. 
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